December 18, 2013

In this latest installment of her Industry Insights column published December 9, 2013, NAI President Rita Numerof, Ph.D., discusses the growing use of risk sharing agreements (RSAs) by private and public payers in contracts with pharmaceutical manufacturers.

Titled Key Considerations for Entering Into Risk Sharing, Rita’s column discusses strategies to develop effective RSAs with insurer networks, the key considerations for manufacturers both prior to and throughout implementation, and the opportunities and risks associated with this particular marketing approach.